Biotech Mesoblast to be hit with class action over COVID-19 treatment disclosures

Advanced Search

Please login to bookmark

Class Actions 2021-04-22 9:25 pm By Cindy Cameronne Sydney

Make us a preferred source

Please login to bookmark

Australian regenerative medicine company Mesoblast faces a shareholder class action over disclosures related to its Remestemcel-L treatment for COVID-19 complications.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au